Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
News Source : Financial Post
News Summary
- Quantum BioPharma Ltd
- (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions
- Contingent Value Rights (the “CVRs”) will entitle the holder to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds, ultimately recovered by the Company
This news release contains forwardlooking information within the meaning of applicable Canadian and U.S. securities legislation. Generally, but not always, forwardlooking information and statements [+6860 chars]